Teva announces Phase III results for allergy spray; Ipsen gets FDA go-ahead for drug delivery syringe;

> Ipsen Biopharmaceuticals received FDA approval for its low-volume, full-dose, one-time-use syringe made to deliver Somatuline Depot (lanreotide). Release

> Teva ($TEVA) announced positive findings in its phase III clinical study on children suffering from year-round and seasonal allergic rhinitis using QNASL, its waterless aerosol intranasal corticosteroid spray. Release

> Maine-based DoseOne, maker of the DoseOne single-dose dry powder inhaler, is looking for a device or pharmaceutical partner to bring the drug delivery device to market. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.